The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Disruption is a pressing problem in the pharmaceutical world; patient health depends on clinical trial organisers avoiding it ...

The European Union's CHMP has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ Wainzua to treat ATTRv-PN.

For firms unsure about the digital transition, partnering with experienced providers like Controlant simplifies the process ...

The IOF highlights the importance of collaborative efforts in treating osteoporosis, ensuring appropriate care globally.

GSK has announced a £50m ($54.3m) investment in a partnership with the University of Cambridge to expedite R&D in ...

Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.